NASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free NBIX Stock Alerts $139.44 +0.34 (+0.24%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$138.57▼$141.7650-Day Range$130.40▼$142.9652-Week Range$89.04▼$143.35Volume664,650 shsAverage Volume848,068 shsMarket Capitalization$13.88 billionP/E Ratio57.62Dividend YieldN/APrice Target$137.52 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Neurocrine Biosciences alerts: Email Address Neurocrine Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.74 Rating ScoreUpside/Downside1.4% Downside$137.52 Price TargetShort InterestHealthy2.19% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.53Based on 28 Articles This WeekInsider TradingSelling Shares$50.43 M Sold Last QuarterProj. Earnings Growth27.25%From $4.88 to $6.21 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.70 out of 5 starsMedical Sector72nd out of 947 stocksBiological Products, Except Diagnostic Industry9th out of 159 stocks 2.4 Analyst's Opinion Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.74, and is based on 17 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $137.52, Neurocrine Biosciences has a forecasted downside of 1.4% from its current price of $139.44.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.19% of the outstanding shares of Neurocrine Biosciences have been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Previous Next 2.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNeurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.Environmental SustainabilityThe Environmental Impact score for Neurocrine Biosciences is -2.61. Previous Next 2.5 News and Social Media Coverage News SentimentNeurocrine Biosciences has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Neurocrine Biosciences this week, compared to 8 articles on an average week.Search InterestOnly 19 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows25 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $50,433,173.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions93.54% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 27.25% in the coming year, from $4.88 to $6.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 57.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.01.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 57.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 188.85.Price to Earnings Growth RatioNeurocrine Biosciences has a PEG Ratio of 0.89. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 6.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Neurocrine Biosciences Stock (NASDAQ:NBIX)Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Read More NBIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBIX Stock News HeadlinesMarch 17, 2024 | insidertrades.comGeorge J. Morrow Sells 40,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockMarch 13, 2024 | insidertrades.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Ingrid Delaet Sells 200 SharesMarch 18, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: March 12, 2024 | insidertrades.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 100 Shares of StockMarch 17, 2024 | uk.investing.comNeurocrine Biosciences exec sells shares worth over $420kMarch 17, 2024 | uk.investing.comNeurocrine Biosciences director sells $5.58m in stockMarch 17, 2024 | investing.comNeurocrine Biosciences director pops Richard F sells $3.26M in stockMarch 17, 2024 | americanbankingnews.comEric Benevich Sells 75,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockMarch 18, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 16, 2024 | finance.yahoo.comDirector Richard Pops Sells 23,200 Shares of Neurocrine Biosciences Inc (NBIX)March 16, 2024 | finance.yahoo.comNeurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells 3,000 SharesMarch 16, 2024 | finance.yahoo.comAI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic BaseMarch 15, 2024 | finance.yahoo.comNeurocrine Biosciences Is Pioneering Therapies for Neurological DisordersMarch 14, 2024 | finance.yahoo.comNBIX Apr 2024 145.000 callMarch 13, 2024 | markets.businessinsider.comIn-Depth Examination Of 8 Analyst Recommendations For Neurocrine BiosciencesMarch 13, 2024 | markets.businessinsider.comDecoding 8 Analyst Evaluations For Neurocrine BiosciencesMarch 13, 2024 | finance.yahoo.comDirector Richard Pops Sells Shares of Neurocrine Biosciences Inc (NBIX)March 11, 2024 | finance.yahoo.comNeurocrine Biosciences to Participate at Virtual Investor Conferences in MarchMarch 11, 2024 | finance.yahoo.comThe $1 Billion Opportunity Driving IBD Stock Of The Day Neurocrine HigherMarch 6, 2024 | investorplace.com3 Cutting-Edge Biotech Stocks Sitting on the Brink of SuccessMarch 1, 2024 | finance.yahoo.comNeurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells Company SharesFebruary 27, 2024 | prnewswire.comNeurocrine Biosciences to Participate at Investor Conferences in MarchFebruary 25, 2024 | finance.yahoo.comNBIX Dec 2024 200.000 callFebruary 23, 2024 | msn.comNeurocrine Biosciences (NBIX) Price Target Increased by 7.78% to 152.22February 23, 2024 | finance.yahoo.comDirector Richard Pops Sells 15,000 Shares of Neurocrine Biosciences IncFebruary 22, 2024 | markets.businessinsider.comCritical Insights From Arcus Biosciences Analyst Ratings: What You Need To KnowFebruary 17, 2024 | finance.yahoo.comNBIX Mar 2024 120.000 callSee More Headlines Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/07/2024Today3/18/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:NBIX CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees1,400Year FoundedN/APrice Target and Rating Average Stock Price Target$138.92 High Stock Price Target$200.00 Low Stock Price Target$100.00 Potential Upside/Downside-1.4%Consensus RatingModerate Buy Rating Score (0-4)2.74 Research Coverage23 Analysts Profitability EPS (Most Recent Fiscal Year)$2.42 Trailing P/E Ratio57.62 Forward P/E Ratio28.57 P/E Growth0.89Net Income$249.70 million Net Margins13.23% Pretax Margin17.60% Return on Equity12.85% Return on Assets9.02% Debt Debt-to-Equity RatioN/A Current Ratio2.45 Quick Ratio2.40 Sales & Book Value Annual Sales$1.89 billion Price / Sales7.35 Cash Flow$2.58 per share Price / Cash Flow53.96 Book Value$22.72 per share Price / Book6.14Miscellaneous Outstanding Shares99,510,000Free Float95,129,000Market Cap$13.88 billion OptionableOptionable Beta0.25 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Kevin C. Gorman Ph.D. (Age 66)CEO & Director Comp: $1.9MMr. Matthew C. Abernethy (Age 43)Chief Financial Officer Comp: $1.04MMr. Darin M. Lippoldt Esq. (Age 58)Chief Legal Officer & Corporate Secretary Comp: $921.01kMr. Kyle W. Gano Ph.D. (Age 51)Chief Business Development & Strategy Officer Comp: $921.52kDr. Eiry Wyn Roberts M.D. (Age 59)Chief Medical Officer Comp: $1.04MDr. Jude Onyia Ph.D. (Age 59)Chief Scientific Officer Comp: $621.66kJane SorensenHead of Investor RelationsMs. Julie S. Cooke (Age 58)Chief Human Resources Officer Mr. Eric S. Benevich (Age 59)Chief Commercial Officer Comp: $805kMr. David Warren Boyer (Age 44)Chief Corporate Affairs Officer More ExecutivesKey CompetitorsAcceleron PharmaNASDAQ:XLRNRepligenNASDAQ:RGENExelixisNASDAQ:EXELMomenta PharmaceuticalsNASDAQ:MNTAHalozyme TherapeuticsNASDAQ:HALOView All CompetitorsInsiders & InstitutionsEric BenevichSold 75,000 sharesTotal: $10.45 M ($139.38/share)George J. MorrowSold 40,000 sharesTotal: $5.58 M ($139.42/share)Vanguard Group Inc.Bought 150,485 shares on 3/11/2024Ownership: 9.758%Richard F PopsSold 100 sharesTotal: $14,000.00 ($140.00/share)Ingrid DelaetSold 200 sharesTotal: $28,000.00 ($140.00/share)View All Insider TransactionsView All Institutional Transactions NBIX Stock Analysis - Frequently Asked Questions Should I buy or sell Neurocrine Biosciences stock right now? 23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 6 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NBIX shares. View NBIX analyst ratings or view top-rated stocks. What is Neurocrine Biosciences' stock price target for 2024? 23 Wall Street research analysts have issued 12-month target prices for Neurocrine Biosciences' stock. Their NBIX share price targets range from $100.00 to $165.00. On average, they predict the company's share price to reach $137.52 in the next twelve months. This suggests that the stock has a possible downside of 1.4%. View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts. How have NBIX shares performed in 2024? Neurocrine Biosciences' stock was trading at $131.76 at the beginning of 2024. Since then, NBIX stock has increased by 5.8% and is now trading at $139.44. View the best growth stocks for 2024 here. When is Neurocrine Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our NBIX earnings forecast. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings data on Wednesday, February, 7th. The company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.13 by $0.31. The business had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 12.85% and a net margin of 13.23%. The business's revenue was up 25.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.88 EPS. What ETFs hold Neurocrine Biosciences' stock? ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco S&P MidCap Momentum ETF (XMMO), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P MidCap 400 Pure Growth ETF (RFG) and SPDR S&P Biotech ETF (XBI). What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO? 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM). Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.76%), Vanguard Group Inc. (9.76%), Bellevue Group AG (2.44%), Price T Rowe Associates Inc. MD (1.48%), Point72 Asset Management L.P. (1.40%) and Dodge & Cox (1.27%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, George J Morrow, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Leslie V Norwalk, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NBIX) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceDid you make $29,000 two days with AI options trades?Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.